NeOnc Technologies shares surge on positive glioma trial data

Shares of NeOnc Technologies surged on Wednesday after the company reported positive interim data from a Phase 2 clinical trial evaluating its experimental therapy for recurrent glioma.

The trial, which enrolled patients with recurrent high-grade glioma, met its primary endpoint of progression-free survival at 6 months, according to a company statement. The data showed a statistically significant improvement in survival rates compared to historical controls, though specific figures were not disclosed.

NeOnc Technologies, a clinical-stage biopharmaceutical company, said the results support the continued development of its lead candidate, a targeted therapy designed to disrupt tumor growth pathways. The company plans to present detailed findings at an upcoming medical conference and consult with regulators on next steps, including potential discussions regarding a pivotal trial design.

The stock, which had been trading near 52-week lows prior to the announcement, jumped more than 30% in premarket trading on the news. Analysts noted that while the data is preliminary, the positive signal could strengthen investor confidence in the biotech sector’s oncology pipeline.

NeOnc Technologies did not respond to requests for additional comment. The company’s market capitalization remains modest, reflecting its early-stage focus, but the trial results underscore the high-risk, high-reward nature of biotech investing.